Differential effects of Tat proteins derived from HIV-1 subtypes B and recombinant CRF02-AG on human brain microvascular endothelial cells: Implications for blood-brain barrier dysfunction

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 6, 2014, Pages 1047-1059

  Woollard, Shawna M ^a   Bhargavan, Biju ^a   Yu, Fang ^b   Kanmogne, Georgette D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

brain endothelium; complement; HIV 1 CRF02 AG; matrix metalloproteinases; subtype B; Tat proteins; viral genetic diversity

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CHEMOKINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C7; MACROPHAGE ELASTASE; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSACTIVATOR PROTEIN;

ARTICLE; BLOOD BRAIN BARRIER; CLADISTICS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE CRF02 AG; MICROVASCULAR ENDOTHELIAL CELL; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VIRUS GENE; VIRUS PATHOGENESIS;

BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; CHEMOKINES; COLLAGENASES; COMPLEMENT C3; COMPLEMENT C7; ENDOTHELIAL CELLS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; SPECIES SPECIFICITY; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84901822969     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.54     Document Type: Article

References (41)

1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799. (Pubitemid 350059308)
2. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-185. (Pubitemid 41043883)
3. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neu-roimmune Pharmacol 2006; 1: 223-236. (Pubitemid 44244128)
4. Banks WA, Ercal N, Price TO. The blood-brain barrier in neuroAIDS. Curr HIV Res 2006; 4: 259-266. (Pubitemid 44027716)
5. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375: 497-500.
6. Banks WA, Robinson SM, Nath A. Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 2005; 193: 218-227. (Pubitemid 40463283)
7. Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O et al. Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol 2000; 6: 145-155. (Pubitemid 30303573)
8. Toborek M, Lee YW, Pu H, Malecki A, Flora G, Garrido R et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem 2003; 84: 169-179. (Pubitemid 36182077)
9. Eugenin EA, King JE, Nath A, Calderon TM, Zukin RS, Bennett MV et al. HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci USA 2007; 104: 3438-3443. (Pubitemid 46364177)
10. Matzen K, Dirkx AE, oude Egbrink MG, Speth C, Gotte M, Ascherl G et al. HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res 2004; 104: 145-155. (Pubitemid 38891750)
11. UNAIDS. GLOBAL REPORT: UNAIDS Report on the global AIDS epidemic. UNAIDS.org 2012.
12. LANL. HIV and SIV Nomenclature. http://www.hiv.lanl.gov/2013.
13. Carr JK, Salminen MO, Albert J, Sanders-Buell E, Gotte D, Birx DL et al. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G inter-subtype recombinants. Virology 1998; 247: 22-31. (Pubitemid 28384022)
14. Montavon C, Toure-Kane C, Liegeois F, Mpoudi E, Bourgeois A, Vergne L et al. Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG. J Acquir Immune Defic Syndr 2000; 23: 363-374. (Pubitemid 30431592)
15. Brennan CA, Bodelle P, Coffey R, Devare SG, Golden A, Hackett Jr. J et al. The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr 2008; 49: 432-439
16. PRB. 2010 World Population Data Sheet, http://www.prb.org/2010.
17. Ranga U, Shankarappa R, Siddappa NB, Ramakrishna L, Nagendran R, Mahalingam M et al. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 2004; 78: 2586-2590. (Pubitemid 38228954)
18. Campbell GR, Watkins JD, Singh KK, Loret EP, Spector SA. Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol 2007; 81: 5919-5928. (Pubitemid 46847028)
19. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15: 293-299. (Pubitemid 32163814)
20. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42: 843-852. (Pubitemid 43363943)
21. Yang B, Singh S, Bressani R, Kanmogne GD. Cross-talk between STAT1 and PI3K/AKT signaling in HIV-1-induced blood-brain barrier dysfunction: role of CCR5 and implications for viral neuropathogenesis. J Neurosci Res 2010; 88: 3090-3101.
22. Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J et al. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci USA 1989; 86: 6925-6929. (Pubitemid 19240844)
23. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359. (Pubitemid 350298459)
24. Carroll MV, Sim RB. Complement in health and disease. Adv Drug Deliv Rev 2011; 63: 965-975.
25. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neu-rotoxicity. J Neurochem 1999; 73: 578-586. (Pubitemid 29339830)
26. Silvers JM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM. Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology 2007; 28: 1184-1190. (Pubitemid 350026595)
27. Zhou BY, Liu Y, Kim B, Xiao Y, He JJ. Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes. Mol Cell Neurosci 2004; 27: 296-305. (Pubitemid 39439968)
28. Xu R, Feng X, Xie X, Zhang J, Wu D, Xu L. HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9. Brain Res 2012; 1436: 13-19.
29. Mastroianni CM, Liuzzi GM. Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 2007; 13: 449-459. (Pubitemid 350086978)
30. Nagase H. Stromelysins 1 and 2. In: Parks WC, Mecham RP (eds) Matrix Metallo-proteinases. Academic Press: San Diego, 1998, pp 43-84.
31. Roe K, Kumar M, Lum S, Orillo B, Nerurkar VR, Verma S. West Nile virus-induced disruption of the blood-brain barrier in mice is characterized by the degradation of the junctional complex proteins and increase in multiple matrix metallopro-teinases. J Gen Virol 2012; 93(Pt 6): 1193-1203.
32. Hummel V, Kallmann BA, Wagner S, Fuller T, Bayas A, Tonn JC et al. Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules. J Neuropathol Exp Neurol 2001; 60: 320-327. (Pubitemid 32274047)
33. Yang Y, Thompson JF, Taheri S, Salayandia VM, McAvoy TA, Hill JW et al. Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery. J Cereb Blood Flow Metab 2013; 33: 1104-1114.
34. Zhang X, Yin P, Di D, Luo G, Zheng L, Wei J et al. IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line. Anticancer Res 2009; 29: 4497-4501.
35. Le Quement C, Guenon I, Gillon JY, Lagente V, Boichot E. MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1076-L1084.
36. Power C, Henry S, Del Bigio MR, Larsen PH, Corbett D, Imai Y et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003; 53: 731-742. (Pubitemid 36622510)
37. Zhou J, Stohlman SA, Atkinson R, Hinton DR, Marten NW. Matrix metalloprotei-nase expression correlates with virulence following neurotropic mouse hepatitis virus infection. J Virol 2002; 76: 7374-7384. (Pubitemid 34760960)
38. Boyer V, Desgranges C, Trabaud MA, Fischer E, Kazatchkine MD. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4-and antibody-independent fashion. J Exp Med 1991; 173: 1151-1158.
39. Speth C, Stockl G, Mohsenipour I, Wurzner R, Stoiber H, Lass-Florl C et al. Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes. J Virol 2001; 75: 2604-2615. (Pubitemid 32185023)
40. Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, Lemmens WA, Hommes OR, Lamers KJ. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 2000; 101: 116-121. (Pubitemid 30051381)
41. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093-1107.